Loading…
Trident Texofab (BSE 540726)₹21.50−2.23%Other Textile Products
In the Jun 2026 quarter (standalone), Trident Texofab reported sales of ₹26.06 Cr, down 6.9% from Jun 2025, and net profit of ₹0.53 Cr, down 48.5% year on year. For the year to Mar 2026, sales were ₹118 Cr and net profit ₹1.01 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 23.12 | 22.93 | 30.07 | 25.62 | 26.34 | 31.57 | 38.08 | 28.00 | 30.54 | 25.63 | 33.47 | 26.06 |
| Expenses | 21.99 | 21.18 | 29.24 | 24.26 | 26.78 | 29.47 | 36.97 | 26.09 | 28.24 | 24.17 | 34.74 | 24.78 |
| Operating Profit | 1.25 | 1.89 | 1.01 | 1.53 | −0.26 | 2.33 | 1.34 | 2.08 | 2.49 | 1.63 | −1.07 | 1.41 |
| OPM % | 5.4% | 8.2% | 3.4% | 5.9% | −1.0% | 7.3% | 3.5% | 7.4% | 8.1% | 6.4% | −3.2% | 5.4% |
| Other Income | 1.04 | 0.12 | 0.40 | 0.87 | 2.77 | −0.21 | 0.44 | 0.45 | 0.40 | 0.39 | −0.51 | 0.20 |
| Interest | 1.06 | 0.92 | 1.13 | 1.04 | 1.12 | 1.37 | 0.98 | 0.72 | 0.95 | 0.86 | 0.36 | 0.54 |
| Depreciation | 0.42 | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 | 0.42 | 0.40 | 0.40 | 0.40 | 0.37 | 0.39 |
| Profit before tax | 0.80 | 0.66 | −0.13 | 0.91 | 0.94 | 0.32 | 0.37 | 1.36 | 1.49 | 0.73 | −2.32 | 0.67 |
| Tax % | 7.4% | 16.5% | −28.5% | 25.0% | −6.3% | 6.1% | −34.2% | 25.6% | 25.4% | 23.0% | −13.7% | 23.6% |
| Exceptional items | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 | 0.05 | −0.04 | 0.00 | 0.00 | −0.09 | −0.88 | 0.00 |
| Net Profit | 0.76 | 0.57 | −0.11 | 0.71 | 1.01 | 0.31 | 0.52 | 1.03 | 1.14 | 0.58 | −2.02 | 0.53 |
| EPS (Rs) | 0.75 | 0.57 | −0.11 | 0.71 | 1.00 | 0.30 | 0.39 | 0.69 | 0.76 | 0.39 | −1.35 | 0.36 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 65.71 | 75.72 | 84.69 | 86.63 | 90.63 | 49.80 | 83.67 | 95.67 | 98.67 | 122 | 118 | 116 |
| Expenses | 65.16 | 75.26 | 84.28 | 85.27 | 86.24 | 47.11 | 79.28 | 88.29 | 92.29 | 115 | 113 | 112 |
| Operating Profit | 0.99 | 1.01 | 0.99 | 1.99 | 5.01 | 2.99 | 4.99 | 8.01 | 7.99 | 6.99 | 4.99 | 4.46 |
| OPM % | 1.5% | 1.5% | 1.7% | 2.8% | 5.0% | 6.0% | 6.0% | 9.0% | 8.0% | 6.0% | 4.3% | 3.9% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 1.01 | 2.01 | 1.01 | 3.01 | 1.01 | 0.48 |
| Interest | 0.99 | 0.99 | 0.99 | 0.99 | 2.99 | 2.99 | 2.99 | 5.98 | 5.98 | 5.98 | 2.99 | 2.71 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 1.99 | 1.99 | 2.01 | 1.99 | 1.56 |
| Profit before tax | 0.00 | 0.99 | 0.99 | 1.99 | 1.99 | 0.99 | 0.99 | 2.99 | 0.99 | 2.99 | 0.99 | 0.57 |
| Tax % | 33.0% | 43.0% | 28.0% | 25.0% | 41.0% | 60.0% | 23.0% | 19.0% | 8.0% | 3.0% | 45.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | −1.01 | −0.97 |
| Net Profit | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 0.00 | 1.01 | 2.01 | 1.01 | 3.01 | 1.01 | 0.23 |
| EPS (Rs) | 0.76 | 4.13 | 0.79 | 1.33 | 0.95 | 0.36 | 0.98 | 2.21 | 1.08 | 1.86 | 0.48 | 0.16 |
| Dividend payout % | 0.0% | 0.0% | 53.0% | 32.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.34 | 0.34 | 0.34 | 4.02 | 4.02 | 4.01 | 10.04 | 10.04 | 10.03 | 10.04 | 14.05 | 15.06 |
| Reserves | 2.99 | 2.99 | 2.99 | 3.99 | 6.97 | 6.98 | 1.99 | 2.99 | 4.98 | 5.98 | 33.87 | 40.94 |
| Borrowings | 4.01 | 3.01 | 5.01 | 5.01 | 15.03 | 22.04 | 34.05 | 39.06 | 38.07 | 40.10 | 30.08 | 37.09 |
| Other Liabilities | 21.03 | 31.03 | 15.02 | 32.01 | 21.04 | 22.04 | 21.95 | 18.93 | 23.95 | 25.92 | 24.12 | 19.10 |
| Total Liabilities | 28.04 | 38.04 | 24.03 | 45.03 | 47.06 | 56.07 | 68.03 | 71.02 | 77.03 | 82.04 | 101 | 111 |
| Fixed Assets | 2.01 | 0.99 | 0.99 | 1.99 | 2.01 | 11.99 | 14.01 | 21.99 | 22.99 | 21.98 | 20.01 | 16.99 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 5.99 | 0.00 | 8.99 | 3.99 | 0.00 | 0.00 | 0.00 | 0.99 |
| Investments | 0.00 | 0.00 | 0.99 | 2.99 | 0.99 | 0.99 | 1.99 | 1.99 | 3.99 | 3.99 | 1.99 | 3.99 |
| Other Assets | 27.03 | 36.05 | 22.05 | 41.05 | 37.07 | 42.09 | 42.04 | 44.05 | 50.05 | 56.07 | 79.12 | 90.22 |
| Inventories | 6.63 | 9.40 | 2.32 | 5.09 | 3.94 | 10.13 | 8.03 | 7.29 | 10.68 | 13.59 | 16.01 | 20.63 |
| Trade receivables | 18.84 | 25.95 | 15.36 | 32.04 | 29.30 | 26.34 | 30.19 | 30.75 | 33.74 | 36.56 | 40.60 | 48.42 |
| Cash & equivalents | 0.21 | 0.15 | 1.85 | 0.22 | 0.38 | 0.07 | 0.02 | 0.03 | 0.05 | 0.15 | 3.15 | 0.10 |
| Total Assets | 28.04 | 38.04 | 24.03 | 45.03 | 47.06 | 56.07 | 68.03 | 71.02 | 77.03 | 82.04 | 101 | 111 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 0.00 | 0.99 | 0.00 | −1.99 | −2.99 | −2.99 | 1.99 | 0.99 | 5.99 | 2.99 | −13.99 | −9.99 |
| Cash from investing activity | 0.99 | 0.00 | −0.99 | −1.99 | −6.99 | −1.99 | −9.99 | −3.99 | 0.00 | −0.99 | −19.98 | −5.99 |
| Cash from financing activity | −1.01 | −1.01 | 2.01 | 3.01 | 10.04 | 5.02 | 8.02 | 3.01 | −6.02 | −2.01 | 37.10 | 12.03 |
| Net cash flow | 0.00 | 0.00 | 2.01 | −1.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.99 | −3.01 |
| Capex | 0.00 | 0.00 | 0.00 | 0.43 | 7.59 | 1.70 | 9.91 | 4.15 | 0.21 | 0.05 | 0.00 | 0.51 |
| Free cash flow | 1.01 | 1.01 | 0.00 | −3.01 | −10.01 | −4.01 | −7.99 | −2.01 | 6.01 | 3.01 | −14.01 | −10.01 |
| CFO / OP % | 4.0% | 79.0% | 27.1% | −140.9% | −83.9% | −48.9% | 76.1% | 29.1% | 73.1% | 36.1% | −182.9% | −172.9% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 109 | 143 | 73 | 136 | 122 | 105 | 220 | 133 | 127 | 134 | 121 | 149 |
| Inventory days | 42 | 55 | 13 | 24 | 19 | 48 | 71 | 38 | 49 | 60 | 56 | 72 |
| Days payable | 127 | 179 | 75 | 135 | 89 | 74 | 141 | 58 | 80 | 73 | 51 | 45 |
| Cash conversion cycle | 25 | 21 | 12 | 26 | 54 | 80 | 151 | 114 | 98 | 122 | 127 | 177 |
| Working capital days | 14 | 11 | 23 | 32 | 37 | 43 | 71 | 42 | 36 | 35 | 89 | 127 |
| ROCE % | 11.9% | 13.0% | 15.9% | 13.9% | 12.0% | 13.9% | 9.0% | 8.0% | 15.9% | 11.9% | 9.9% | 6.0% |
For the Jun 2026 quarter, Trident Texofab reported sales of ₹26.06 Cr, down 6.9% year on year and net profit of ₹0.53 Cr, down 48.5% year on year. The operating margin was 5.4%.
Trident Texofab's sales for the year to Mar 2026 were ₹118 Cr; over the last twelve months they were ₹116 Cr.
Net profit for the year to Mar 2026 was ₹1.01 Cr, and ₹0.23 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.16.
Trident Texofab reported borrowings of ₹37.09 Cr at Mar 2026, against cash and equivalents of ₹0.10 Cr.
Cash from operations was −₹9.99 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹10.01 Cr.